RECRO PHARMA INC's ticker is REPH and the CUSIP is 75629F109. A total of 56 filers reported holding RECRO PHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $440,319 | +17.1% | 938,847 | +174.5% | 0.05% | +24.3% |
| Q2 2023 | $376,160 | -17.9% | 341,964 | -11.2% | 0.04% | -21.3% |
| Q1 2023 | $458,432 | -49.4% | 385,237 | -36.6% | 0.05% | -58.4% |
| Q4 2022 | $905,422 | +129.8% | 607,666 | +151.7% | 0.11% | +105.5% |
| Q3 2022 | $394,000 | +99.0% | 241,472 | -2.8% | 0.06% | +111.5% |
| Q2 2022 | $198,000 | -58.8% | 248,472 | -6.9% | 0.03% | -52.7% |
| Q1 2022 | $481,000 | -7.7% | 266,972 | -12.3% | 0.06% | -3.5% |
| Q4 2021 | $521,000 | +644.3% | 304,533 | +793.0% | 0.06% | +5600.0% |
| Q3 2021 | $70,000 | -11.4% | 34,103 | -0.9% | 0.00% | -90.0% |
| Q2 2021 | $79,000 | -76.1% | 34,403 | -70.9% | 0.01% | -76.7% |
| Q1 2021 | $330,000 | +148.1% | 118,232 | +153.3% | 0.04% | +126.3% |
| Q4 2020 | $133,000 | -36.1% | 46,682 | +83.5% | 0.02% | -60.4% |
| Q1 2020 | $208,000 | – | 25,438 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MAK CAPITAL ONE LLC | 850,129 | $2,423,000 | 0.65% |
| Newtyn Management, LLC | 700,000 | $1,995,000 | 0.46% |
| Portolan Capital Management | 1,293,376 | $3,686,000 | 0.34% |
| Rubric Capital Management LP | 1,076,587 | $3,068,000 | 0.22% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 99,046 | $282,000 | 0.04% |
| Alyeska Investment Group, L.P. | 736,821 | $2,100,000 | 0.03% |
| STEPHENS INC /AR/ | 510,569 | $1,455,000 | 0.03% |
| Clear Harbor Asset Management, LLC | 46,682 | $133,000 | 0.02% |
| WYNNEFIELD CAPITAL INC | 13,000 | $37,000 | 0.02% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 451,301 | $1,286,000 | 0.01% |